Cargando…

Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs

BACKGROUND: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response. HYPOTHESIS/OBJECTIVES: To determine if the progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Allstadt, S.D., Rodriguez, C.O., Boostrom, B., Rebhun, R.B., Skorupski, K.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858101/
https://www.ncbi.nlm.nih.gov/pubmed/25619518
http://dx.doi.org/10.1111/jvim.12533
_version_ 1782430752090095616
author Allstadt, S.D.
Rodriguez, C.O.
Boostrom, B.
Rebhun, R.B.
Skorupski, K.A.
author_facet Allstadt, S.D.
Rodriguez, C.O.
Boostrom, B.
Rebhun, R.B.
Skorupski, K.A.
author_sort Allstadt, S.D.
collection PubMed
description BACKGROUND: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response. HYPOTHESIS/OBJECTIVES: To determine if the progression‐free interval (PFI) of dogs with TCC treated with mitoxantrone and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of mitoxantrone is no different from carboplatin. ANIMALS: Fifty dogs with TCC without azotemia. METHODS: Prospective open‐label phase III randomized study. Either mitoxantrone or carboplatin was administered every 3 weeks concurrently with piroxicam with restaging at 6‐week intervals. Twenty‐four dogs received carboplatin and 26 received mitoxantrone. RESULTS: Response was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group, there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD). In the carboplatin group, there were 3 PR (13%) and 13 (54%) dogs with SD. The PFI was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47–1.56). Dogs with prostatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically located tumors; this difference was significant (median 300, 190, and 645 days, respectively; P = .005). CONCLUSIONS AND CLINICAL IMPORTANCE: This study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam.
format Online
Article
Text
id pubmed-4858101
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48581012016-06-22 Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs Allstadt, S.D. Rodriguez, C.O. Boostrom, B. Rebhun, R.B. Skorupski, K.A. J Vet Intern Med Standard Articles BACKGROUND: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response. HYPOTHESIS/OBJECTIVES: To determine if the progression‐free interval (PFI) of dogs with TCC treated with mitoxantrone and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of mitoxantrone is no different from carboplatin. ANIMALS: Fifty dogs with TCC without azotemia. METHODS: Prospective open‐label phase III randomized study. Either mitoxantrone or carboplatin was administered every 3 weeks concurrently with piroxicam with restaging at 6‐week intervals. Twenty‐four dogs received carboplatin and 26 received mitoxantrone. RESULTS: Response was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group, there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD). In the carboplatin group, there were 3 PR (13%) and 13 (54%) dogs with SD. The PFI was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47–1.56). Dogs with prostatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically located tumors; this difference was significant (median 300, 190, and 645 days, respectively; P = .005). CONCLUSIONS AND CLINICAL IMPORTANCE: This study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam. John Wiley and Sons Inc. 2015-01-25 2015 /pmc/articles/PMC4858101/ /pubmed/25619518 http://dx.doi.org/10.1111/jvim.12533 Text en Copyright © 2015 by the American College of Veterinary Internal Medicine
spellingShingle Standard Articles
Allstadt, S.D.
Rodriguez, C.O.
Boostrom, B.
Rebhun, R.B.
Skorupski, K.A.
Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs
title Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs
title_full Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs
title_fullStr Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs
title_full_unstemmed Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs
title_short Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs
title_sort randomized phase iii trial of piroxicam in combination with mitoxantrone or carboplatin for first‐line treatment of urogenital tract transitional cell carcinoma in dogs
topic Standard Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858101/
https://www.ncbi.nlm.nih.gov/pubmed/25619518
http://dx.doi.org/10.1111/jvim.12533
work_keys_str_mv AT allstadtsd randomizedphaseiiitrialofpiroxicamincombinationwithmitoxantroneorcarboplatinforfirstlinetreatmentofurogenitaltracttransitionalcellcarcinomaindogs
AT rodriguezco randomizedphaseiiitrialofpiroxicamincombinationwithmitoxantroneorcarboplatinforfirstlinetreatmentofurogenitaltracttransitionalcellcarcinomaindogs
AT boostromb randomizedphaseiiitrialofpiroxicamincombinationwithmitoxantroneorcarboplatinforfirstlinetreatmentofurogenitaltracttransitionalcellcarcinomaindogs
AT rebhunrb randomizedphaseiiitrialofpiroxicamincombinationwithmitoxantroneorcarboplatinforfirstlinetreatmentofurogenitaltracttransitionalcellcarcinomaindogs
AT skorupskika randomizedphaseiiitrialofpiroxicamincombinationwithmitoxantroneorcarboplatinforfirstlinetreatmentofurogenitaltracttransitionalcellcarcinomaindogs